Publish date:

How Kaleo Pharma Prices Its EpiPen Competitor

Kaleo's EpiPen compeitor the Auvi-Q was released today.

While Mylan (MYL) - Get Mylan N.V. (MYL) Report has consistently made headlines for controversy over the pricing of its EpiPen, an auto-injector used to treat anaphylaxis and severe food allergies, there's more to the pricing of its competitor than meets the eye. Released today, Kaleo's Auvi-Q will cost insurers 9 times more than the Epipen. In response, Express Scripts (ESRX) , UnitedHealth Group (UNH) - Get UnitedHealth Group Incorporated Report and Cigna (CI) - Get Cigna Corporation Report will not cover the device.

This article was written by a staff member of TheStreet.

TheStreet Recommends